{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:40:10Z","timestamp":1764603610216},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,3,15]]},"DOI":"10.2169\/internalmedicine.3772-19","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T22:04:49Z","timestamp":1574373889000},"page":"829-833","source":"Crossref","is-referenced-by-count":4,"title":["Nivolumab for Methotrexate-associated Classic Hodgkin's Lymphoma in a Rheumatoid Arthritis Patient"],"prefix":"10.2169","volume":"59","author":[{"given":"Keisuke","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Kuboki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Koi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Toyota","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yokosuka Kyosai Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236: 219-242, 2010.","DOI":"10.1111\/j.1600-065X.2010.00923.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J 20: 265-271, 2014.","DOI":"10.1097\/PPO.0000000000000059"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99: 12293-12297, 2002.","DOI":"10.1073\/pnas.192461099"},{"key":"4","unstructured":"4. Yamazaki N, Kiyohara Y, Uhara H, et al. Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: a phase II study. Cancer Sci 108: 1223-1230, 2017."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hida T, Nishio M, Nogami N, et al. Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer. Cancer Sci 108: 1000-1006, 2017.","DOI":"10.1111\/cas.13225"},{"key":"6","doi-asserted-by":"crossref","first-page":"e000108","DOI":"10.1136\/esmoopen-2016-000108","volume":"1","author":"M Nishio","year":"2017","unstructured":"6. Nishio M, Hida Y, Atagi S, et al. Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. ESMO Open 1: e000108, 2017.","journal-title":"ESMO Open","ISSN":"http:\/\/id.crossref.org\/issn\/2059-7029","issn-type":"print"},{"key":"7","unstructured":"7. Tomita Y, Fukasawa S, Shinohara N, et al. Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. Jpn J Clin Oncol 47: 639-646, 2017."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372: 311-319, 2015.","DOI":"10.1056\/NEJMoa1411087"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Maruyama D, Hatake K, Kinoshita T, et al. Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin's lymphoma. Cancer Sci 108: 1007-1012, 2017.","DOI":"10.1111\/cas.13230"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front Pharmacol 8: 1-14, 2017.","DOI":"10.3389\/fphar.2017.00049"},{"key":"11","unstructured":"11. Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 328: 1317-1321, 1993."},{"key":"12","unstructured":"12. Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Hematol 91: 20-28, 2013."},{"key":"13","unstructured":"13. Gion Y, Iwaki N, Takata K, et al. Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma and classical Hodgkin's lymphoma types. Cancer Sci 108: 1271-1280, 2017."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Tokuhira M, Saito S, Okuyama A, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma 59: 1143-1152, 2018.","DOI":"10.1080\/10428194.2017.1369073"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kurita D, Miyoshi H, Ichikawa A, et al. Methotrexate-associated lymphoproliferative disorders in patients with rheumatoid arthritis clinicopathologic features and prognostic factors. Am J Surg Pathol 43: 869-884, 2019.","DOI":"10.1097\/PAS.0000000000001271"},{"key":"16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2016.07.001","volume":"99","author":"K Ikeuchi","year":"2016","unstructured":"16. Ikeuchi K, Okuma Y, Tabata T. Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: a case report. Lung Cancer 99: 148-150, 2016.","journal-title":"Lung Cancer","ISSN":"http:\/\/id.crossref.org\/issn\/0169-5002","issn-type":"print"},{"key":"17","unstructured":"17. Friedman CF, Clark V, Raikhel AV, et al. Thinking critically about classifying adverse events: incidence of pancreatitis in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst 109: 1-3, 2017."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Gutzmer R, Koop A, Meier F, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmune or ipilimumab-triggered autoimmunity. Eur J Cancer 75: 24-32, 2017.","DOI":"10.1016\/j.ejca.2016.12.038"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28: 368-376, 2017.","DOI":"10.1093\/annonc\/mdw443"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Leonardi GC, Gainor JF, Altan M, et al. Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders. J Clin Oncol 36: 1905-1912, 2018.","DOI":"10.1200\/JCO.2017.77.0305"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin's lymphoma and predict outcome. J Clin Oncol 34: 2690-2697, 2016.","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"22","unstructured":"22. Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17: 1283-1294, 2016."},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Mariette X, Hatem DC, Warszawki J, Liote F, Balandraud N, Sibilia J. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99: 3909-3915, 2002.","DOI":"10.1182\/blood.V99.11.3909"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Nakazato T, Takanashi S, Hirano M, et al. Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin's lymphoma. Ann Hematol 97: 1489-1491, 2018.","DOI":"10.1007\/s00277-018-3279-8"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/6\/59_3772-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T03:41:06Z","timestamp":1584762066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/6\/59_3772-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,15]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3772-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,15]]}}}